Pharmaceutical Patent Services

Pharmaceutical Patents
We offer a full range of patent application preparation and prosecution services. We have many professionals with advanced degrees in chemistry and the life sciences. Our attorneys and patent agents have drafted and prosecuted applications for small molecule pharmaceuticals, biopharmaceuticals, bioinformatics, personalized medicine, polymorphs, pharmaceutical formulations, methods of treatment, methods of manufacture, and diagnostic methods. We can also assist you in obtaining patent term extensions for patent office and regulatory agency delays.

Patent Review Proceedings
A variety of pre-grant and post-grant patent review options are available under the AIA. In some instances these proceeding can be used to contest patents as effectively as litigation but at a much lower cost. We can assist you with pre-issuance submissions, re-examinations, inter partes review, and post grant review proceedings. We also provide assistance with supplemental examinations and re-examinations to patent owners who wish to insure the strength and validity of their patents.

Opinions
Our attorneys are experienced in preparing invalidity, non-infringement, patentability, and freedom to operate opinions for our generic, biotechnology, and drug discovery clients. All our attorneys are trained in patent searching. Our extensive in-house prior art searching capabilities allow us to deliver high quality legal opinions at a cost that is typically lower than the cost for legal opinions from firms which use primarily outsourced searches. The scientific expertise of our professionals is used to provide design-around strategies to clients concerned about freedom to operate or patent infringement. Our design-around strategies include non-infringement strategies for Orange-book listed patents.

Competitive Intelligence
Understanding your competitors’ intellectual property is essential in the pharmaceutical and biotechnology industries. We help by providing landscape services in areas such as API, process chemistry, formulation, and methods of use patents. Our landscape reports allow you to quickly view your competitors’ patents and patent applications that may impact your business goals. We also offer patent monitoring services of competitors’ patent grants, patent publications, prosecution, national stage entry, litigation, and post-grant proceedings.

Pharmaceutical Licensing
Our licensing professionals deliver a full range of licensing services to our generic, biotechnology, and drug discovery clients including technology transfer agreements, confidentiality agreements, research agreements, and end user
agreements. We can assist you in structuring strategic alliances and joint development agreements. We also provide intellectual property due diligence services for clients involved in mergers and acquisitions.

**Patent portfolio management**
We provide a variety of patent portfolio management strategies to our clients including national phase filing strategies, parallel patent prosecution in multiple jurisdictions, and life cycle management strategies.

**Biosimilar and Interchangeable Biological Drugs**
We have the expertise to assist you in negotiating the FDA process for licensing biosimilar and interchangeable biological drugs for marketing. We can help you identify reference product patent, provide invalidity, unenforceability, and non-infringement statements, and assist in all aspects of the patent dispute resolution process, including litigation.

**News**

Cantor Colburn Expands Atlanta Office
August 27, 2018

Cantor Colburn is the #1 Law Firm for Handling Mayo/Myriad Rejections
*Juristat*
August 16, 2017
(James Cosgrove)

Fed. Circ. Upholds Invalidity Of Purdue’s Sleep Aid Patents
January 11, 2016

Will Biosimilar Applicants Opt Out of Patent Dance?
*The Connecticut Law Tribune*
April 20, 2015
(Leslie-Anne Maxwell, Andrew C. Ryan, Steven M. Coyle)

Cantor Colburn Generic Pharmaceutical Client Dr. Reddy’s Prevails At Trial On Sleep Drug
*Press Release*
March 31, 2015

Purdue’s Sleep Aid Patents Are Obvious, Judge Rules
*IP Law360*
March 30, 2015
(Aaron Vehling)

BPCIA: How Long Does The Party Last And Do I Have To Dance?
*Law360*
March 24, 2015
(Leslie-Anne Maxwell, Andrew Ryan, Christopher Potts, Derek Denhart)

3 Things To Watch After Sandoz’s Biosimilars Win
*Law360*
March 20, 2015
(Jeff Overley)
Purple Book Launches New Chapter in Generic Drugs  
October 20, 2014  
(Anne Maxwell)

Cantor Colburn Article: Diagnostic Method Patents In Doubt  
*Connecticut Law Tribune*  
April 27, 2014  
(Leslie-Anne Maxwell)

Publications

*Amgen v Sandoz: The Biosimilars Saga Continues*  
*Life Sciences IP Review*  
October 27, 2015  
(Steve Coyle and Leslie-Anne Maxwell)

Events

9th Annual Pharma IPR Summit  
March 4, 2020  
Mumbai, India  
Cantor Colburn is pleased to sponsor the 9th Annual Pharma IPR Conference in Mumbai, India, on March 4-6, 2020. Steve Coyle and Anne Maxwell, Ph.D., Esq., co-chairs of the Pharmaceutical IP Services Practice Group, will attend, as will Nick Geiger.

BioCT’s Annual Bioscience Holiday Celebration & Networking Party  
December 10, 2019  
New Haven, CT  

Paragraph IV Disputes Master Symposium 2019  
October 3, 2019  
Chicago  
The Paragraph IV Disputes Master Symposium will take place in Chicago on October 3-4, 2019. Litigators Steve Coyle and Tasia Perkins will attend.

Cantor Colburn has a dedicated Pharmaceutical Practice Group comprised of experienced litigators, Ph.D. chemists, and patent attorneys.

The 5th Annual Bioscience & Beer Mixer  
September 19, 2019  
Branford, Connecticut  
BioCT is holding its annual Bioscience & Beer Mixer on September 19, 2019 in Branford, Connecticut. Many members of Cantor Colburn’s Life Sciences Practice Group will attend. Cantor Colburn is a long-standing BioCT sponsor.
Women Leaders in Life Sciences Law
July 25, 2019
Boston
Anne Maxwell, Ph.D., Esq. and Tina Dorr, Ph.D., Esq. will attend the Women Leaders in Life Sciences Law conference in Boston on July 25-26, 2019.

Pharma IPR India 2019
March 6, 2019
Mumbai
Cantor Colburn is pleased to sponsor the 8th Annual Pharma IPR Conference in Mumbai, India, on March 6-8, 2019. Steve Coyle, who leads the Pharmaceutical IP Services Practice Group and co-chairs the Litigation Department, will speak on "ANDA Filing and Litigation: Procedures to Respond."

The 5th Annual JAX Healthcare Forum
October 24, 2018
Farmington, Connecticut
Cantor Colburn is pleased to be a returning sponsor of The 5th Annual JAX Healthcare Forum, which focuses on emerging science and technology that will change the future of healthcare, and innovations in healthcare. Todd E. Garabedian, Ph.D., Partner and Vice Chair of the Life Sciences Practice Group, is on the planning committee for this forum and will attend the event.

6th Annual Paragraph IV Master Disputes Symposium
October 1, 2018
Chicago, Illinois
The 6th Annual Paragraph IV Disputes Master Symposium will take place in Chicago on October 1-3, 2018. Cantor Colburn has a dedicated Pharmaceutical Practice Group comprised of experienced litigators, Ph.D. chemists, and patent attorneys. Litigators Steve Coyle and Nicholas Geiger will attend.

Managing IP Life Sciences Forum 2018
September 12, 2018
New York City
Pharmaceutical Practice Group Co-Chair and partner Anne Maxwell, Ph.D. will attend the Managing IP Life Sciences Forum on September 12, 2018 in New York City. The conference brings together industry leaders, inhouse and outside counsel, and members of the judiciary to discuss the latest decisions and significant changes affecting the life sciences industry today.

Paragraph IV Disputes Conference
April 23, 2018
New York City
Cantor Colburn is sponsoring the Paragraph IV Disputes conference in New York City on April 23-25, 2018. Cantor Colburn has a dedicated Pharmaceutical Practice Group comprised of experienced litigators, Ph.D. chemists, and patent attorneys.

Pharma IPR India 2018
March 7, 2018
Mumbai, India
Cantor Colburn is pleased to sponsor the 7th Annual Pharma IPR Conference in Mumbai, India, on March 7-9, 2018. Cantor Colburn's Pharmaceutical IP Services Practice Group handles litigation, patent prosecution, inter partes reviews
and other Patent Office review proceedings, opinions, landscapes, competitive intelligence, transactional services, portfolio management, biosimilar and interchangeable biological drugs, and more. Steve Coyle, who leads the Pharmaceutical Litigation Group, will speak on "ANDA filling and litigation: strategies to respond."

Summit on Due Diligence
November 2, 2017
Philadelphia, Pennsylvania

Stem Conn 2017
April 27, 2017
New Haven, Connecticut
Stem Conn is Connecticut's largest scientific conference, with 500 participants from academia, industry, and government. The 2017 event took place on April 27 at the Omni in New Haven.

Paragraph IV Disputes Conference
April 24, 2017
New York, New York
Cantor Colburn litigation partner Steve Coyle moderated the panel "The Ongoing Jurisdiction Debate: From Mylan to TC Heartland" at the Paragraph IV Disputes Conference in New York City, which the firm also sponsored. Cantor Colburn has a dedicated Pharmaceutical Practice Group comprised of experienced litigators, Ph.D. chemists, and patent attorneys.

Pharma and IP Legal Summit
December 7, 2016
Morristown, New Jersey
Leslie-Anne Maxwell, Ph.D., Partner and Co-Chair of the Pharmaceutical IP Services Practice, spoke on "Pharma Patent Battles" at the Pharma and IP Legal Summit in Morristown, New Jersey on December 7th.

2016 BIO International Convention
June 6, 2016
San Francisco, California
Anne Maxwell, Ph.D. and Todd Garabedian, Ph.D. are attending the BIO International Convention (BIO) in San Francisco, June 6-9, 2016.

The Myriad Decision — Impact on Entrepreneurship In Diagnostics and Customized Medicines
March 25, 2014
Yale School of Medicine, New Haven, Connecticut
Cantor Colburn partner Anne Maxwell, Ph.D., joins a CURE panel discussion of the Association for Molecular Pathology v. Myriad Genetics decision and its impact on entrepreneurship in diagnostics and customized medicines at the Yale School of Medicine in New Haven on Tuesday, March 25, from 4-6 PM. This BioHaven seminar has convened a panel of experts from various sectors of the biotech and pharmaceutical industry to discuss the business implications of cases such as Myriad.